# MyCustom:Prospective Master Protocol Trial on Precision Medicine Treatment for Refractory Solid Tumors

> **NCT06030869** · — · UNKNOWN · sponsor: **Tianjin Medical University Second Hospital** · enrollment: 400 (estimated)

## Conditions studied

- Refractory Solid Tumors
- Next Generation Sequencing

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06030869
- **Lead sponsor:** Tianjin Medical University Second Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-01
- **Primary completion:** 2023-12-30
- **Final completion:** 2023-12-31
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2023-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06030869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06030869, "MyCustom:Prospective Master Protocol Trial on Precision Medicine Treatment for Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06030869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*